Apeloa Pharmaceutical
Native name | 普洛药业股份有限公司 |
|---|---|
| Company type | Subsidiary |
| SZSE: 000739 | |
| Industry | Chemicals, Pharmaceutical, Biotechnology |
| Founded | 1989 |
| Products | APIs, FDFs, CDMO services |
| Revenue |
|
| Owner |
|
Number of employees | 7,400+ (2025)[1] |
Apeloa Pharmaceutical Co., Ltd. (Chinese: 普洛药业股份有限公司), known as Apeloa, is a Chinese pharmaceutical manufacturer under Hengdian Group. The company is headquartered in Hengdian, Dongyang, Zhejiang, China.[2][3] It was founded in 1989 and has been listed on the Shenzhen Stock Exchange since 9 May 1997 (ticker: 000739).[4][5] Apeloa provides contract development and manufacturing (CDMO) services and manufactures APIs and finished dosage forms; products span cardiovascular, anti-infective, psychiatric and oncology areas.[6][4]
Apeloa has 7400 employees, 8 manufacturing sites and 3 R&D centers in Boston, Shanghai and Hengdian, covering flow chemistry, synthetic biology and biocatalysis, and peptide development.[7] It has invested over USD20 million in flow chemistry over the past ten years in an effort to advance sustainable pharmaceutical manufacturing.[8] In Boston, its 17,000-square-foot facility does R&D related to chemistry needs in drug development, including preclinical chemistry, scale-up production and new drug development.[9]
Apeloa Pharmaceutical has successfully passed 20 U.S. FDA inspections since 2006.[10]
In 2022, Apeloa Pharmaceutical was one of five Chinese companies licensed to produce Pfizer's oral Covid-19 treatment for lower-income countries.[11] The agreement was signed with the Medicines Patent Pool (MPP), an organization that aims to increase access to drugs in 95 lower-income countries.[12]
Apeloa is a subsidiary of Hengdian Group, a major Chinese private conglomerate founded in 1975 in Hengdian, Zhejiang, with businesses spanning electronics, pharmaceuticals/healthcare, film & tourism, and modern services.[13][14]
See also
References
- ^ "关于普洛". 普洛药业 (in Chinese). Retrieved 28 September 2025.
- ^ "Contact Us". Apeloa. Retrieved 28 September 2025.
- ^ "Apeloa Pharmaceutical Co., Ltd". Hengdian Group. Retrieved 28 September 2025.
- ^ a b "About Apeloa". Apeloa. Retrieved 28 September 2025.
- ^ "个股信息：000739 普洛药业". Shenzhen Stock Exchange (in Chinese). Retrieved 28 September 2025.
- ^ "Apeloa Pharmaceutical Co Ltd (000739.SZ) – Company Profile". Reuters. Retrieved 28 September 2025.
- ^ "Advancing Sustainable Pharmaceutical Manufacturing with Flow Chemistry". BioSpectrumAsia. 27 August 2025. Retrieved 8 November 2025.
- ^ "Advancing Sustainable Pharmaceutical Manufacturing with Flow Chemistry". BioSpectrumAsia. 27 August 2025. Retrieved 8 November 2025.
- ^ "Apeloa Opens 17,000 Sq. Ft. CDMO R&D Center in Billerica". PharmaSource Global. 11 September 2024. Retrieved 1 November 2025.
- ^ Sternberg, Charlie (30 October 2025). "Apeloa Pharmaceutical Passes 20th FDA Inspection". Contract Pharma. Retrieved 8 November 2025.
- ^ Ouyang, Iris (18 March 2022). "Fosun Pharmaceutical among five Chinese firms licensed to produce generic version of Pfizer's oral Covid-19 drug". South China Morning Post. Retrieved 8 November 2025.
- ^ "Nirmatrelvir". Medicines Patent Pool. Retrieved 8 November 2025.
- ^ "集团简介". Hengdian Group (in Chinese). Retrieved 28 September 2025.
- ^ Informa Connect. "Apeloa Pharmaceutical". Informa. Retrieved 8 November 2025.